{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:43:29Z","timestamp":1760784209963},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13104-016-2301-2","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T12:19:09Z","timestamp":1480335549000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report"],"prefix":"10.1186","volume":"9","author":[{"given":"Z.","family":"Ballatore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pistelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Battelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pagliacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"De Lisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cascinu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"key":"2301_CR1","unstructured":"American Cancer Society. Cancer facts and figures\u00a02014. http:\/\/www.cancer.org\/acs\/groups\/content\/@research\/documents\/webcontent\/acspc-042151.pdf . Accessed 2 Sept 2014."},{"issue":"8","key":"2301_CR2","doi-asserted-by":"publisher","first-page":"678","DOI":"10.7326\/0003-4819-137-8-200210150-00013","volume":"137","author":"SH Giordano","year":"2002","unstructured":"Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137(8):678\u201387. doi: 10.7326\/0003-4819-137-8-200210150-00013 .","journal-title":"Ann Intern Med"},{"issue":"5","key":"2301_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/bcr2930","volume":"13","author":"J White","year":"2011","unstructured":"White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V. Male breast carcinoma: increased awareness needed. Breast Cancer Res. 2011;13(5):219. doi: 10.1186\/bcr2930 .","journal-title":"Breast Cancer Res"},{"key":"2301_CR4","unstructured":"Ferlay J, Steliarova-Foucher E, Forman D. Cancer incidence in five continents, CI5plus: IARC Cancer Base No. 9. 2014. http:\/\/ci5.iarc.fr . Accessed 19 Dec 2014."},{"key":"2301_CR5","unstructured":"Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide: IARC CancerBase No. 11. 2013. http:\/\/globocan.iarc.fr . Accessed 29 Jul 2014."},{"key":"2301_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0039-6060(99)70135-2","volume":"126","author":"CE Scott-Conner","year":"1999","unstructured":"Scott-Conner CE, Jochimsen PR, Menck HR, Winchester DJ. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery. 1999;126:775\u201380. doi: 10.1016\/S0039-6060(99)70135-2 .","journal-title":"Surgery"},{"key":"2301_CR7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1365-2354.2012.01365.x","volume":"21","author":"TS Dabakuyo","year":"2012","unstructured":"Dabakuyo TS, Dialla O, Gentil J, Poillot ML, Roignot P, Cuisenier J, et al. Breast cancer in men in Cote d\u2019Or (France): epidemiological characteristics, treatments and prognostic factors. Eur J Cancer Care. 2012;21:809\u201316. doi: 10.1111\/j.1365-2354.2012.01365.x .","journal-title":"Eur J Cancer Care."},{"issue":"2","key":"2301_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-008-0053-y","volume":"115","author":"V Speirs","year":"2009","unstructured":"Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treat. 2009;115(2):429\u201330. doi: 10.1007\/s10549-008-0053-y .","journal-title":"Breast Cancer Res Treat"},{"key":"2301_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cncr.20312","volume":"101","author":"SH Giordano","year":"2004","unstructured":"Giordano SH, Cohen D, Buzdar A, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004;101:51\u20137. doi: 10.1002\/cncr.20312 .","journal-title":"Cancer"},{"key":"2301_CR10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00000421-200206000-00006","volume":"25","author":"SH Giordano","year":"2002","unstructured":"Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol. 2002;25:235\u20137.","journal-title":"Am J Clin Oncol"},{"key":"2301_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/annonc\/mdp450","volume":"25","author":"A Italiano","year":"2004","unstructured":"Italiano A, Largillier R, Marcy PY, Foa C, Ferrero JM, Hartmann MT, et al. Complete remission obtained with letrozole in a man with metastatic breast cancer. Rev Med Intern. 2004;25:323\u20134. doi: 10.1093\/annonc\/mdp450 .","journal-title":"Rev Med Intern"},{"issue":"1","key":"2301_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/jso.20233","volume":"90","author":"BP Zabolotny","year":"2005","unstructured":"Zabolotny BP, Zalai CV, Meterissian SH. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol. 2005;90(1):26\u201330. doi: 10.1002\/jso.20233 .","journal-title":"J Surg Oncol"},{"key":"2301_CR13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12094-007-0034-3","volume":"9","author":"E Arriola","year":"2007","unstructured":"Arriola E, Hui E, Dowsett M, Smith EI. Aromatase inhibitors and male breast cancer. Clin Transl Oncol. 2007;9:192\u20134. doi: 10.1007\/s12094-007-0034-3 .","journal-title":"Clin Transl Oncol"},{"key":"2301_CR14","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.breast.2005.08.032","volume":"15","author":"N Steele","year":"2006","unstructured":"Steele N, Zekri J, Coleman R, Leonard R, Dunn K, Bowman A, et al. Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast. 2006;15:430\u20136. doi: 10.1016\/j.breast.2005.08.032 .","journal-title":"Breast"},{"issue":"12","key":"2301_CR15","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","volume":"25","author":"M Piccart","year":"2014","unstructured":"Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25(12):2357\u201362. doi: 10.1093\/annonc\/mdu456 .","journal-title":"Ann Oncol"},{"key":"2301_CR16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/annonc\/mdp450","volume":"21","author":"J Doyen","year":"2010","unstructured":"Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A. Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol. 2010;21:1243\u20135. doi: 10.1093\/annonc\/mdp450 .","journal-title":"Ann Oncol"},{"key":"2301_CR17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/0960-0760(92)90369-T","volume":"41","author":"AS Bhatnagar","year":"1992","unstructured":"Bhatnagar AS, M\u00fcller P, Schenkel L, Trunet PF, Beh I, Schieweck K. Inhibition of estrogen biosynthesis and its consequences on gonadotrophin secretion in the male. J Steroid Biochem Mol Biol. 1992;41:437\u201343. doi: 10.1016\/0960-0760(92)90369-T .","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2301_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1210\/jcem.77.2.8345034","volume":"77","author":"PF Trunet","year":"1993","unstructured":"Trunet PF, Mueller P, Bhatnagar AS, Dickes I, Monnet G, White G. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab. 1993;77:319\u201323. doi: 10.1210\/jcem.77.2.8345034 .","journal-title":"J Clin Endocrinol Metab"},{"key":"2301_CR19","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1210\/jcem.85.7.6676","volume":"85","author":"N Mauras","year":"2000","unstructured":"Mauras N, O\u2019Brien KO, Klein KO, Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab. 2000;85:2370\u20137. doi: 10.1210\/jcem.85.7.6676 .","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2301_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10549-013-2675-y","volume":"141","author":"L Lauro Di","year":"2013","unstructured":"Di Lauro L, Vici P, Del Medico P, Laudadio L, Tomao S, Giannarelli D, et al. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast Cancer Res Treat. 2013;141(1):119\u201323. doi: 10.1007\/s10549-013-2675-y .","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2301_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10549-014-3087-3","volume":"147","author":"M Maugeri-Sacc\u00e0","year":"2014","unstructured":"Maugeri-Sacc\u00e0 M, Barba M, Vici P, Pizzuti L, Sergi D, De Maria R, et al. Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. Breast Cancer Res Treat. 2014;147(2):227\u201335. doi: 10.1007\/s10549-014-3087-3 .","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"2301_CR22","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s10637-014-0133-2","volume":"32","author":"J Kattan","year":"2014","unstructured":"Kattan J, Kourie HR. The use of everolimus to reverse tamoxifen resistance in men with metastatic breast cancer: a case report. Invest New Drugs. 2014;32(5):1046\u20137. doi: 10.1007\/s10637-014-0133-2 .","journal-title":"Invest New Drugs"},{"key":"2301_CR23","unstructured":"Bent E, Guy HMJ, Sara A, Richard HH, Taran De Boer T, Shmoud T et al. BOLERO-6: Phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR+, HER2\u2212 advanced breast cancer. 2013 ASCO Annual Meeting. J Clin Oncol 31, 2013 (suppl; abstr TPS660). https:\/\/clinicaltrials.gov\/show\/NCT01783444 ."},{"issue":"8","key":"2301_CR24","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1007\/s00520-013-1826-3","volume":"21","author":"ME Peterson","year":"2013","unstructured":"Peterson ME. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer. 2013;21(8):2341\u20139. doi: 10.1007\/s00520-013-1826-3 .","journal-title":"Support Care Cancer"},{"issue":"7","key":"2301_CR25","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3109\/0284186X.2012.705019","volume":"51","author":"R Iacovelli","year":"2012","unstructured":"Iacovelli R, Palazzo A, Mezi S, Morano F, Naso G, Cortesi E. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol. 2012;51(7):873\u20139. doi: 10.3109\/0284186X.2012.705019 .","journal-title":"Acta Oncol"},{"issue":"9","key":"2301_CR26","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2217\/fon.14.31","volume":"10","author":"E Verzoni","year":"2014","unstructured":"Verzoni E, Pusceddu S, Buzzoni R, Garanzini E, Damato A, Biondani P, et al. Safety profile and treatment response of everolimus in different solid tumors: an observational study. Future Oncol. 2014;10(9):1611\u20137. doi: 10.2217\/fon.14.31 .","journal-title":"Future Oncol"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-016-2301-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T04:37:43Z","timestamp":1498365463000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-016-2301-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,28]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2301"],"URL":"https:\/\/doi.org\/10.1186\/s13104-016-2301-2","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,28]]},"article-number":"497"}}